ArticleClinical kidney journal2026
Impact of denosumab on bone high-resolution peripheral quantitative computed tomography in hemodialysis patients: a retrospective longitudinal observational study.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and hypothesis: Denosumab increases bone mineral density (BMD) in dialysis patients, but the effects on bone microarchitecture using high-resolution peripheral quantitative computed tomography (HRpQCT) and the response factors to treatment are unknown. Methods: We analyzed, at a single center between 2014 and 2024, 19 consecutive patients on hemodialysis having a longitudinal HRpQCT monitoring at the distal tibia and radius. After excluding the presence of osteomalacia based on bone biopsies and ensuring well-controlled parathyroid hormone levels, nine patients with recent fractures were treated with denosumab. Changes in HRpQCT parameters observed over time were analyzed within the denosumab group and were compared to a group of a nontreated patients, using linear mixed models for repeated measures. Baseline histomorphometric parameters were analyzed as predictors of changes in HRpQCT parameters over time in denosumab-treated patients. Results: During a median [maximum-minimum] follow-up period of 2.1 [1.0-3.5] years, the nine denosumab-treated patients had a significant improvement of (i) bone volume-to-total volume ratio at the distal radius (+1.63% [95% confidence interval: 1.11-3.31] per year, Conclusion: Denosumab improves HRpQCT trabecular bone parameters without significant effect on cortical parameters in dialysis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.